V. Ghetie and E. S. Ward, Multiple Roles for the Major Histocompatibility Complex Class I-Related 671

, Receptor FcRn, Annu. Rev. Immunol, vol.18, pp.739-766, 2000.

D. C. Roopenian and S. Akilesh, FcRn: the neonatal Fc receptor comes of age, Nat. Rev. Immunol, vol.7, pp.715-725, 2007.

E. S. Ward, S. C. Devanaboyina, and R. J. Ober, Targeting FcRn for the modulation of antibody 675 dynamics, Mol. Immunol, vol.67, pp.131-141, 2015.

M. Pyzik, T. Rath, W. I. Lencer, K. Baker, R. S. Blumberg et al., The Architect Behind the

, Immune and Nonimmune Functions of IgG and Albumin, J. Immunol. Baltim. Md, vol.678, pp.4595-4603, 2015.

D. C. Roopenian, The MHC Class I-Like IgG Receptor Controls Perinatal IgG Transport

, Homeostasis, and Fate of IgG-Fc-Coupled Drugs, J. Immunol, vol.170, pp.3528-3533, 2003.

L. D'hooghe, A. D. Chalmers, S. Heywood, and P. Whitley, Cell surface dynamics and cellular 682 distribution of endogenous FcRn, PloS One, vol.12, p.182695, 2017.

D. K. Challa, R. Velmurugan, R. J. Ober, and E. Ward, FcRn: from molecular interactions to 684 regulation of IgG pharmacokinetics and functions, Curr. Top. Microbiol. Immunol, vol.382, p.685, 2014.

W. I. Lencer and R. S. Blumberg, A passionate kiss, then run: exocytosis and recycling of IgG by

. Fcrn, Trends Cell Biol, vol.15, pp.5-9, 2005.

L. M. Sánchez, D. M. Penny, and P. J. Bjorkman, Stoichiometry of the interaction between the 689 major histocompatibility complex-related Fc receptor and its Fc ligand, Biochemistry, vol.38, pp.9471-690, 1999.

Y. N. Abdiche, The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG 11, Conformational Destabilization of Immunoglobulin G Increases the Low pH

, Binding Affinity with the Neonatal Fc Receptor, J. Biol. Chem, vol.291, pp.1817-1825, 2016.

W. L. Martin, A. P. West, L. Gan, and P. J. Bjorkman, Crystal Structure at 2.8 Å of an

. Fcrn, Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding, Mol. Cell, vol.7, pp.867-877, 2001.

V. Oganesyan, Structural Insights into Neonatal Fc Receptor-based Recycling Mechanisms

, J. Biol. Chem, vol.289, pp.7812-7824, 2014.

P. Morgan, Can the flow of medicines be improved? Fundamental pharmacokinetic and 701 pharmacological principles toward improving Phase II survival, Drug Discov. Today, vol.17, p.702, 2012.

A. V. Kamath, Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies

, Drug Discov. Today Technol. 21, vol.22, pp.75-83, 2016.

J. Zalevsky, Enhanced antibody half-life improves in vivo activity, Nat. Biotechnol, vol.28, pp.157-706, 2010.

W. F. Dall'acqua, Increasing the affinity of a human IgG1 for the neonatal Fc receptor: 708 biological consequences, J. Immunol. Baltim. Md, vol.169, pp.5171-5180, 1950.

W. F. Dall'acqua, P. A. Kiener, and H. Wu, Properties of Human IgG1s Engineered for Enhanced 710 Binding to the Neonatal Fc Receptor (FcRn), J. Biol. Chem, vol.281, pp.23514-23524, 2006.

W. R. Strohl, Current progress in innovative engineered antibodies, Protein Cell, vol.9, pp.86-120, 2018.

M. J. Borrok, pH-Dependent Binding Engineering Reveals An FcRn Affinity Threshold Which

, Governs IgG Recycling. J. Biol. Chem. jbc.M114, vol.603712, 2014.

G. J. Robbie, A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, p.717

. Motavizumab-yte, Has an Extended Half-Life in Healthy Adults, Antimicrob. Agents Chemother

A. Datta-mannan, FcRn Affinity-Pharmacokinetic Relationship of Five Human IgG4

, Antibodies Engineered for Improved In Vitro FcRn Binding Properties in Cynomolgus Monkeys

, Drug Metab. Dispos, vol.40, pp.1545-1555, 2012.

Q. Zhu, A highly potent extended half-life antibody as a potential RSV vaccine surrogate for 723 all infants, Sci. Transl. Med, vol.9, 2017.

S. Ko, Enhanced neonatal Fc receptor function improves protection against primate SHIV 725 infection, Nature, vol.514, pp.642-645, 2014.

C. Vaccaro, R. Bawdon, S. Wanjie, R. J. Ober, and E. S. Ward, Divergent activities of an 727 engineered antibody in murine and human systems have implications for therapeutic antibodies

, Proc. Natl. Acad. Sci, vol.103, pp.18709-18714, 2006.

, FDA approved | PNH treatment

. Npd_bwe,

J. B. Domachowske, Tolerability, and Pharmacokinetics of MEDI8897, p.733

, Half-Life Single-Dose Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody 734

, Administered as a Single Dose to Healthy Preterm Infants, Pediatr. Infect. Dis. J, p.735, 2018.

A. Datta-mannan, D. R. Witcher, Y. Tang, J. Watkins, V. J. Wroblewski et al., Monoclonal Antibody, vol.30

, Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates, Drug Metab

. Dispos, , vol.35, pp.86-94, 2007.

Y. Zheng, Translational pharmacokinetics and pharmacodynamics of an FcRn-variant anti-743 CD4 monoclonal antibody from preclinical model to phase I study, Clin. Pharmacol. Ther, vol.89, pp.283-290, 2011.

P. R. Cooper, The contribution of cell surface FcRn in monoclonal antibody serum uptake 746 from the intestine in suckling rat pups, Front. Pharmacol, vol.5, 2014.

W. Wang, Monoclonal Antibodies with Identical Fc Sequences Can Bind to FcRn 748 Differentially with Pharmacokinetic Consequences, Drug Metab. Dispos, vol.39, pp.1469-1477, 2011.

M. J. Borrok, An 'Fc-Silenced' IgG1 Format With Extended Half-Life Designed for Improved

. Stability, J. Pharm. Sci, vol.106, pp.1008-1017, 2017.

A. Grevys, Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor 752

, Affects Fc Effector Functions, J. Immunol, vol.194, pp.5497-5508, 2015.

D. Roopenian, G. Christianson, G. Proetzel, and . Sproule, ThomasJ. Human FcRn, vol.754

, Transgenic Mice for Pharmacokinetic Evaluation of Therapeutic Antibodies, Mouse Models for

G. Proetzel and M. V. Wiles, , p.756, 2016.

G. Proetzel and D. C. Roopenian, Humanized FcRn mouse models for evaluating pharmacokinetics 758 of human IgG antibodies, Methods San Diego Calif, vol.65, pp.148-153, 2014.

S. Latvala, B. Jacobsen, M. B. Otteneder, A. Herrmann, and S. Kronenberg,

, Across Species and Tissues, J. Histochem. Cytochem. Off. J. Histochem. Soc, vol.65, pp.321-333, 2017.

J. T. Andersen, M. B. Daba, G. Berntzen, T. E. Michaelsen, and I. Sandlie,

S. H. Tam, S. G. Mccarthy, K. Brosnan, K. M. Goldberg, and B. J. Scallon, Correlations between 765 pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model 766 with predictive capabilities, mAbs, vol.5, pp.397-405, 2013.

S. Kasturirangan, Targeted Fc? Receptor (Fc?R)-mediated Clearance by a Biparatopic 768

, Bispecific Antibody. J. Biol. Chem, vol.292, pp.4361-4370, 2017.

P. Khare, Myelin oligodendrocyte glycoprotein-specific antibodies from multiple sclerosis 770 patients exacerbate disease in a humanized mouse model, J. Autoimmun, vol.86, pp.104-115, 2018.

S. T. Jung, Effective Phagocytosis of Low Her2 Tumor Cell Lines with Engineered, p.772

, Aglycosylated IgG Displaying High Fc?RIIa Affinity and Selectivity, ACS Chem. Biol, vol.8, pp.368-375, 2012.

C. Lee, IgG Fc domains that bind C1q but not effector Fc? receptors delineate the 775 importance of complement-mediated effector functions, Nat. Immunol, vol.18, pp.889-898, 2017.

B. R. Harvey, Anchored periplasmic expression, a versatile technology for the isolation of 777 high-affinity antibodies from Escherichia coli-expressed libraries, Proc. Natl. Acad. Sci. U. S. A, vol.778, pp.9193-9198, 2004.

T. H. Kang, An Engineered Human Fc variant with Exquisite Selectivity for Fc?RIIIaV158

, Reveals that Ligation of Fc?RIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis 781 with GM-CSF-differentiated Macrophages, Front. Immunol, vol.10, 2019.

X. Yu, Engineering hydrophobic protein-carbohydrate interactions to fine-tune monoclonal 783 antibodies, J. Am. Chem. Soc, vol.135, pp.9723-9732, 2013.

C. Monnet, Selection of IgG Variants with Increased FcRn Binding Using Random and 785

, Directed Mutagenesis: Impact on Effector Functions. Front. Immunol, vol.6, 2015.

A. Grevys, Mechanisms of anaphylaxis in human low-affinity IgG receptor locus knock-in 789 mice, J. Allergy Clin. Immunol, vol.139, 2017.

H. Beutier, Platelets expressing IgG receptor Fc?RIIA/CD32A determine the severity of 791 experimental anaphylaxis, Sci. Immunol, vol.3, p.5997, 2018.

P. Bruhns, Properties of mouse and human IgG receptors and their contribution to disease 793 models, Blood, vol.119, pp.5640-5649, 2012.

N. J. Zvaifler, The Immunopathology of Joint Inflammation in Rheumatoid Arthritis11Original 795 work described in this review has been aided by grants

, National Institutes of Health, Advances in Immunology

F. Ingegnoli, R. Castelli, and R. Gualtierotti, Rheumatoid factors: clinical applications, Dis. Markers, vol.799, pp.727-734, 2013.

M. M. Newkirk, Rheumatoid factors: host resistance or autoimmunity?, Clin. Immunol. Orlando

, Fla, vol.104, pp.1-13, 2002.

D. M. Lee, Mast cells: a cellular link between autoantibodies and inflammatory arthritis

, Science, vol.297, pp.1689-1692, 2002.

A. Jarasch, Developability Assessment During the Selection of Novel Therapeutic

. Antibodies, J. Pharm. Sci, vol.104, pp.1885-1898, 2015.

T. Jain, Biophysical properties of the clinical-stage antibody landscape, Proc. Natl. Acad. Sci

U. S. , , vol.114, pp.944-949, 2017.

P. Bruhns, Specificity and affinity of human Fc? receptors and their polymorphic variants 814 for human IgG subclasses, Blood, vol.113, pp.3716-3725, 2009.

M. B. Overdijk, Crosstalk between Human IgG Isotypes and Murine Effector Cells

. Immunol, , vol.189, pp.3430-3438, 2012.

C. Stein, Clinical chemistry of human FcRn transgenic mice, Mamm. Genome Off. J. Int

, Mamm. Genome Soc, vol.23, pp.259-269, 2012.

J. C. Almagro, T. R. Daniels-wells, S. M. Perez-tapia, and M. L. Penichet, Progress and Challenges 820 in the Design and Clinical Development of Antibodies for Cancer Therapy, Front. Immunol, vol.8, p.821, 2018.

Y. Feng, R. Gong, D. S. Dimitrov, and . Design, expression and characterization of a soluble single-823 chain functional human neonatal Fc receptor, Protein Expr. Purif, vol.79, pp.66-71, 2011.

W. Kelton, IgGA: a 'cross-isotype' engineered human Fc antibody domain that displays 825 both IgG-like and IgA-like effector functions, Chem. Biol, vol.21, pp.1603-1609, 2014.

Y. Kawarasaki, Enhanced crossover SCRATCHY: construction and high-throughput 827 screening of a combinatorial library containing multiple non-homologous crossovers

, Acids Res, vol.31, p.126, 2003.

C. Chaudhury, The major histocompatibility complex-related Fc receptor for IgG (FcRn) 830 binds albumin and prolongs its lifespan, J. Exp. Med, vol.197, pp.315-322, 2003.

, Stan: A Probabilistic Programming Language | Carpenter, Journal of Statistical Software, vol.832, p.69

, SINS) assay. Data are from one experiment representative of three experiments using three individual 882 donors (a-d). Errors in all plots and tables represent standard deviations from triplicate experiments